Cervical Cancer

Norway Chooses The Four-Type HPV Vaccine Gardasil(R) For The National Vaccination Programme
The four-type (6,11,16,18) human papillomavirus (HPV) vaccine, Gardasil®, has been chosen by the Norwegian authorities for the national vaccination programme after the assessment of a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection. All available data was considered, including new data presented during the 25th International Papillomavirus Conference (IPC) in May in Malmö, Sweden.